Evidence map›Paper›PMID 24969622›Full record

ReviewCurrent neurology and neuroscience reports2014

Emergency reversal of anticoagulation: novel agents.

Michael Levine, Joshua N Goldstein

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Diagnosis and Management of Acute Intracerebral Hemorrhage.Emergency medicine clinics of North America · 2016
    Review
  3. New Oral Anticoagulants and Their Reversal Agents.Current treatment options in neurology · 2016
    Review
  4. Anticoagulation drug therapy: a review.The western journal of emergency medicine · 2015
    Review
  5. Review
  6. Risk Factors for Pulmonary Embolism in ICU Patients: A Retrospective Cohort Study from the MIMIC-III Database.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Michael LevineDepartment of Emergency Medicine, Section of Medical Toxicology, University of Southern California, 1200 North State Street, Room 1011, Los Angeles, CA, 90033, USA, mdlevine@usc.edu.
Joshua N Goldstein

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Historically, oral anticoagulation involved the administration of vitamin K antagonists, such as warfarin. However, because of the need for frequent monitoring and the desire for safer anticoagulants, several novel oral anticoagulants have been developed. These newer agents include the factor Xa inhibitors (eg, rivaroxaban, apixaban, edoxaban), along with the direct thrombin inhibitors (eg, dabigatran). This manuscript provides a brief overview of their uses and mechanisms of action, along with a review of currently available evidence for reversal strategies when life-threatening bleeding occurs.

Indexed as

AnticoagulantsAntithrombinsFactor Xa InhibitorsHumansAnticoagulantsAntithrombinsFactor Xa Inhibitors

Identifiers

PMID24969622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.